Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
It remains the first and only FDA-approved obesity treatment that activates both GIP and GLP-1 receptors, making it potentially more potent than previous GLP-1 medications solely targeting GLP-1 for weight management
PT-141 is effective for treating various sexual health concerns in both men and women: For Men: Erectile dysfunction that has or has not responded to traditional treatments Low libido and decreased sexual desire Performance anxiety affecting sexual function Men seeking alternatives to PDE5 inhibitors Lack of penile sensitivity and/or pleasure For Women: Hypoactive Sexual Desire Disorder (HSDD) Female sexual arousal disorder Decreased libido during perimenopause and menopause Low sexual satisfaction and reduced sensitivity For Couples: Mismatched libido between partners Relationship intimacy challenges Age-related changes in sexual function Desire to enhance the overall sexual experience What Benefits Can I Expect from PT-141 Therapy
consults for Novo Nordisk and is the founder of Antag Pharmaceuticals
